Organization | University of Exeter

University of Exeter Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Devon United Kingdom (1838)

Organization Overview

First Clinical Trial

2004

NCT00334711

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Devon Partnership NHS Trust | Institue of Biomedical and Clinical Sciences, Peninsula Medical School, University of Exeter | Peninsula Medical School, Exeter | Peninsula Medical School, Exeter, UK | Peninsular Medical School, Exeter | Royal Devon and Exeter Hopsitals NHS Trust | Royal Devon and Exeter Hospital | Royal Devon and Exeter Hospital NHS Foundation Trust | Royal Devon and Exeter National Health Service Foundation trust | Royal Devon and Exeter NHS Foundation trust | Royal Devon and Exeter NHS Foundation Trust | Royal Devon & Exeter Hospital | Royal Devon & Exeter Hospital, Exeter UK | The University of Exeter | University of Exeter | University of Exeter, College of Life and Environmental Sciences | University of Exeter Medical School | University of Exeter / Royal Devon & Exeter NHS Trust | University of Exeter, Sport and Health Sciences department | University of Exeter, Sport and Health Sciences Department

Active Ingredients

Drugs in Phase 4 Trials (6)

canagliflozin (invokana) (1 trial)

gliclazide (1 trial)

pioglitazone (actos) (1 trial)

remdesivir (Veklury) (1 trial)

sitagliptin (januvia) (4 trials)

sufonylurea (3 trials)

Drugs in Phase 3 Trials (3)

collagen (1 trial)

posaconazole (noxafil) (1 trial)

vildagliptin (1 trial)

Drugs in Phase 2 Trials (11)

azd-0328 (1 trial)

cannabidiol (Epidiolex) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

inactivated influenza vaccine (1 trial)

ketamine (ketalar) (1 trial)

levobupivacaine (chirocaine) (2 trials)

midazolam (versed) (2 trials)

p.dom-wt1-37 dna vaccine and p.dom-wt1-126 dna vaccine (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

thalidomide (Thalomid) (1 trial)

Drugs in Phase 1 Trials (2)

nicotinamide (1 trial)

pterostilbene (1 trial)

Drugs in Other Trials (39)

acetaminophen (tylenol) (2 trials)

acetylsalicylic acid (aspirin) (1 trial)

Asparagus racemosus (1 trial)

beetroot juice (8 trials)

beta-alanine (1 trial)

blueberry (1 trial)

blueberry allergenic extract (1 trial)

bupivacaine (Exparel) (1 trial)

caffeine (2 trials)

cherry (4 trials)

coffee (1 trial)

cyclizine lactate (marezine) (1 trial)

epinephrine (levophed) (1 trial)

exenatide (byetta) (1 trial)

fentanyl (Innovar) (1 trial)

gentamicin (garamycin) (1 trial)

ibuprofen (motrin) (1 trial)

insulin human (humulin) (1 trial)

ketone (1 trial)

leucovorin (1 trial)

liraglutide (victoza) (3 trials)

magnesium stearate (1 trial)

maltodextrin (2 trials)

morphine (1 trial)

multivitamins (1 trial)

mycoprotein (3 trials)

olbetam (3 trials)

ondansetron (zofran) (1 trial)

propofol (diprivan) (1 trial)

selenium (1 trial)

teicoplanin (1 trial)

tranexamic acid (cyklokapron) (1 trial)

vitamin a (1 trial)

vitamin c (2 trials)

vitamin e (1 trial)

whey protein (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fistula (Phase 3)

Hematologic Neoplasms (Phase 2)

Immunoblastic Lymphadenopathy (Phase 2)

Influenza, Human (Phase 2)

Insulin Resistance (Phase 3)

Joint Diseases (Phase 2)

Leukemia (Phase 2)

Lymphoma (Phase 2)

Pelvic Organ Prolapse (Phase 2)

Prediabetic State (Phase 4)

Prolapse (Phase 2)

Rotator Cuff Injuries (Phase 2)

Rotator Cuff Tear Arthropathy (Phase 2)

Ulcer (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 57
# of Trial APIs: 61